Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
28 07 2020
Historique:
received: 13 05 2020
accepted: 22 06 2020
entrez: 30 7 2020
pubmed: 30 7 2020
medline: 15 5 2021
Statut: ppublish

Résumé

We observed a 55-year-old Italian man who presented with mucosal and cutaneous bleeding. Results of his blood analysis showed low levels of von Willebrand factor (VWF) antigen and VWF activity (both VWF ristocetin cofactor and VWF collagen binding), mild thrombocytopenia, increased ristocetin-induced platelet aggregation, and a deficiency of high-molecular-weight multimers, all typical phenotypic hallmarks of type 2B von Willebrand disease (VWD). The analysis of the VWF gene sequence revealed heterozygous in cis mutations: (1) c.2771G>A and (2) c.6532G>T substitutions in the exons 21 and 37, respectively. The first mutation causes the substitution of an Arg residue with a Gln at position 924, in the D'D3 domain. The second mutation causes an Ala to Ser substitution at position 2178 in the D4 domain. The patient's daughter did not present the same fatherly mutations but showed only the heterozygous polymorphic c.3379C>T mutation in exon 25 of the VWF gene causing the p.P1127S substitution, inherited from her mother. The in vitro expression of the heterozygous in cis VWF mutant rVWFWT/rVWF924Q-2178S confirmed and recapitulated the ex vivo VWF findings. Molecular modeling showed that these in cis mutations stabilize a partially stretched and open conformation of the VWF monomer. Transmission electron microscopy and atomic force microscopy showed in the heterozygous recombinant form rVWFWT/rVWF924Q-2178S a stretched conformation, forming strings even under static conditions. Thus, the heterozygous in cis mutations 924Q/2178S promote conformational transitions in the VWF molecule, causing a type 2B-like VWD phenotype, despite the absence of typical mutations in the A1 domain of VWF.

Identifiants

pubmed: 32722784
pii: S2473-9529(20)31565-2
doi: 10.1182/bloodadvances.2020002334
pmc: PMC7391138
doi:

Substances chimiques

von Willebrand Factor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3405-3415

Informations de copyright

© 2020 by The American Society of Hematology.

Références

FASEB J. 2007 Dec;21(14):3872-6
pubmed: 17606809
Biochem J. 1995 Mar 1;306 ( Pt 2):453-63
pubmed: 7887899
Blood. 2014 Mar 20;123(12):1785-93
pubmed: 24394662
J Biol Chem. 1989 Nov 25;264(33):19514-27
pubmed: 2584182
J Thromb Haemost. 2010 Sep;8(9):1986-93
pubmed: 20492463
Blood. 2010 Dec 9;116(24):5371-6
pubmed: 20570857
J Biol Chem. 2006 Feb 24;281(8):4699-707
pubmed: 16373331
Thromb Haemost. 2016 Jan;115(1):51-62
pubmed: 26272487
BMC Biol. 2007 May 08;5:17
pubmed: 17488521
Biophys J. 2005 Mar;88(3):2022-9
pubmed: 15613637
Proteins. 2007;69 Suppl 8:108-17
pubmed: 17894355
Br J Haematol. 2003 Feb;120(4):627-32
pubmed: 12588349
Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2625-30
pubmed: 22922961
Blood. 2016 Dec 8;128(23):2743
pubmed: 27932330
Proteins. 2011;79 Suppl 10:147-60
pubmed: 22069036
Blood. 1996 Feb 1;87(3):1013-21
pubmed: 8562925
J Thromb Haemost. 2006 Oct;4(10):2103-14
pubmed: 16889557
Hum Genet. 1994 Feb;93(2):95-102
pubmed: 7906671
Annu Rev Biochem. 1998;67:395-424
pubmed: 9759493
PLoS One. 2013 Aug 29;8(8):e73572
pubmed: 24009757
Phys Rev E. 2016 Jan;93(1):012410
pubmed: 26871104
Thromb Haemost. 2008 Oct;100(4):716-8
pubmed: 18841300
J Thromb Haemost. 2008 Apr;6(4):569-76
pubmed: 18208537
EMBO J. 2011 Aug 19;30(19):4098-111
pubmed: 21857647
Thromb Haemost. 2006 Nov;96(5):630-41
pubmed: 17080221
Clin Appl Thromb Hemost. 2006 Oct;12(4):397-420
pubmed: 17000885
J Thromb Haemost. 2010 Sep;8(9):2063-5
pubmed: 20626619
Blood. 1996 Oct 15;88(8):2951-8
pubmed: 8874191
Br J Haematol. 1992 Mar;80(3):358-63
pubmed: 1581215
J Thromb Haemost. 2013 Sep;11(9):1688-98
pubmed: 23819767
Forensic Sci Int. 2002 Oct 9;129(3):148-57
pubmed: 12372685
Thromb Haemost. 2014 Oct;112(4):825-30
pubmed: 25103956
Thromb Haemost. 1993 Jul 1;70(1):99-104
pubmed: 8236123
Blood. 2009 Jan 15;113(3):526-34
pubmed: 18805962
J Thromb Haemost. 2009 Oct;7(10):1672-9
pubmed: 19624459
Blood. 1991 Oct 1;78(7):1738-43
pubmed: 1912563
Haemophilia. 2014 Jul;20(4):559-67
pubmed: 25077350
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):482-7
pubmed: 18182488
Biochemistry. 1986 Jun 3;25(11):3171-84
pubmed: 3524673
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):678-682
pubmed: 27913546
Proteins. 2014 Feb;82 Suppl 2:175-87
pubmed: 23760925
Blood. 2006 Sep 15;108(6):1903-10
pubmed: 16772609
Biomol Concepts. 2019 Nov 27;10(1):194-208
pubmed: 31778361
J Biol Chem. 2000 Aug 18;275(33):25585-94
pubmed: 10831592
Res Pract Thromb Haemost. 2017 Dec 12;2(1):34-41
pubmed: 30046704
Biophys Chem. 2009 Oct;144(3):101-7
pubmed: 19647361
J Physiol. 1999 Oct 1;520 Pt 1:5-14
pubmed: 10517795
J Thromb Haemost. 2016 Feb;14(2):411-4
pubmed: 26882161
Blood. 2012 Jul 12;120(2):449-58
pubmed: 22490677
Eur Biophys J. 2010 Nov;39(12):1597-603
pubmed: 20589372
Haemophilia. 2011 Nov;17(6):944-51
pubmed: 21371195
J Mol Biol. 2016 Feb 22;428(4):693-701
pubmed: 26437129
Blood. 2008 Jan 15;111(2):651-7
pubmed: 17901248
Proc Natl Acad Sci U S A. 2007 May 8;104(19):7899-903
pubmed: 17470810
Blood. 2006 Nov 15;108(10):3344-51
pubmed: 16835381

Auteurs

Monica Sacco (M)

Dipartimento di Medicina e Chirurgia Traslazionale, Facoltà di Medicina e Chirurgia Agostino Gemelli, Università Cattolica S. Cuore, Rome, Italy.

Stefano Lancellotti (S)

Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Mattia Ferrarese (M)

Dipartimento di Scienze della Vita e Biotecnologie, Università di Ferrara, Ferrara, Italy.

Francesco Bernardi (F)

Dipartimento di Scienze della Vita e Biotecnologie, Università di Ferrara, Ferrara, Italy.

Mirko Pinotti (M)

Dipartimento di Scienze della Vita e Biotecnologie, Università di Ferrara, Ferrara, Italy.

Maira Tardugno (M)

Dipartimento di Medicina e Chirurgia Traslazionale, Facoltà di Medicina e Chirurgia Agostino Gemelli, Università Cattolica S. Cuore, Rome, Italy.

Erica De Candia (E)

Dipartimento di Medicina e Chirurgia Traslazionale, Facoltà di Medicina e Chirurgia Agostino Gemelli, Università Cattolica S. Cuore, Rome, Italy.
Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Leonardo Di Gennaro (L)

Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Maria Basso (M)

Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Betti Giusti (B)

Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Florence, Italy.
Laboratorio Genetico Molecolare Avanzato, Struttura Operativa Dipartimentale (SOD) Malattie Aterotrombotiche, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Massimiliano Papi (M)

Dipartimento di Neuroscienze, Facoltà di Medicina e Chirurgia Agostino Gemelli, Università Cattolica S. Cuore, Rome, Italy; and.

Giordano Perini (G)

Dipartimento di Neuroscienze, Facoltà di Medicina e Chirurgia Agostino Gemelli, Università Cattolica S. Cuore, Rome, Italy; and.

Giancarlo Castaman (G)

Centro Malattie Emorragiche e della Coagulazione, Dipartimento di Oncologia, Ospedale Universitario Careggi, Florence, Italy.

Raimondo De Cristofaro (R)

Dipartimento di Medicina e Chirurgia Traslazionale, Facoltà di Medicina e Chirurgia Agostino Gemelli, Università Cattolica S. Cuore, Rome, Italy.
Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH